{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-24-002772","form_type":"8-K","ticker":"VNRX","cik":"0000093314","company_name":"VOLITIONRX LTD","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.544226+00:00","generated_at":"2026-06-02T03:08:10.326864+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"VolitionRx Q1 revenue $170k (+15% YoY); cash $11.8M; targets $10M annual cost cuts for 2025 cash flow neutrality","bullets":["Q1 2024 revenue ~$170,000, up 15% YoY; cash and equivalents $11.8M as of March 31, 2024.","Targeting $10M in annualized cost reductions; aiming for cash flow neutrality in 2025 via non-dilutive funding, revenue growth, and milestone payments.","Applied for $25M in U.S. and $18M in European non-dilutive grants.","Expects substantial Nu.Q NETs and Capture-PCR clinical data by end of June; then laser focus on commercialization.","Volition Vet revenue expected to accelerate in H2 2024 after recent Antech and Fujifilm product launches."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-24-002772","json":"https://secwatch.observer/filing/0001477932-24-002772.json","markdown":"https://secwatch.observer/filing/0001477932-24-002772.md","text":"https://secwatch.observer/filing/0001477932-24-002772.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/93314/000147793224002772/0001477932-24-002772-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/93314/000147793224002772/vnrx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T03:08:10.326864+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ed36df0b20c19e26a143bc623cf7bef0e04440e1","claim":"VOLITIONRX LTD reported the first quarter of 2024 results: revenue approximately $170,000 in revenue.","evidence_excerpt":"recorded approximately $170,000 in revenue in the first quarter of 2024, up 15% over the prior year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/93314/000147793224002772/0001477932-24-002772-index.htm","confidence":0.92,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2024"},{"label":"Revenue","value":"approximately $170,000 in revenue"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}